GE HealthCare reports positive Phase 2 results for mangaciclanol MRI contrast agent and moves to Phase 3
GE HealthCare announced that its investigational manganese‑based MRI contrast agent mangaciclanol met the primary endpoint in the Phase 2 portion of the international LUMINA trial. The agent showed diagnostic preference comparable to gadobutrol and was well tolerated, leading to a selected dose of 0.1 mmol/kg for Phase 3. The U.S. FDA granted Fast Track designation to mangaciclanol, and the company will present the Phase 2 data at the RSNA meeting on 1 December 2026.
Why it matters
The company says the Phase 2 success supports progression to a pivotal Phase 3 study, which could eventually expand its contrast‑media portfolio beyond gadolinium agents. Analysts note that a successful Phase 3 could open a new revenue stream in the $65 billion global contrast‑enhanced MRI market.
Key facts
- 1Phase 2 results met the primary endpoint of overall diagnostic preference, showing similarity between mangaciclanol and gadobutrol. tradingview.com
- 2The dose selected for Phase 3 is 0.1 mmol/kg. ansa.it
- 3Mangaciclanol received Fast Track designation from the U.S. Food and Drug Administration. ansa.it
- 4The first patient was dosed at Mayo Clinic in April 2026, seven months before the Phase 2 readout. ansa.it
- 5GE HealthCare will present preliminary Phase 2 results at RSNA in Chicago on Tuesday 1 December 2026, 12:00‑13:00. finanznachrichten.de
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.